BOCCADASSE – FRIDAY 6 SEPTEMBER

17.30

rFVIIIFc for first-time immune tolerance induction (ITI) therapy: interim results from the global, prospective verITI-8 study
L. Malec (USA)
VIEW ePOSTER

17.40

Brazilian registry of persons with hemophilia A receiving emicizumab (Emicizumab Cases, EMCase Project)
R. Camelo (Brazil)
VIEW ePOSTER

17.50

Nature of FVIII-containing immune complexes and induction of immune tolerance in patients with hemophilia A
M. Bou Jadeh (France)
VIEW ePOSTER

18.00

Performance of a clinical risk prediction model for inhibitor formation in severe hemophilia
S. Hassan (The Netherlands)
VIEW ePOSTER

18.10

Real-World Efficacy and Safety Data of Patients With Hemophilia and Inhibitors Treated With aPCC: “FEIBA Global Outcome Study (FEIBA-GO)”, Results From >12 Months’ Follow-up
Viridiana Cano (Switzerland)

18.20

The timing of initial exposures to FVIII treatment in nonsevere hemophilia A
A. Abdi (The Netherlands)
VIEW ePOSTER

BOCCADASSE – SATURDAY 7 SEPTEMBER

18.30

In-depth epitope mapping of anti-ADAMTS13 autoantibodies in immune-mediated thrombotic thrombocytopenic purpura patients using a large library of ADAMTS13 fragments
K. Kangro (Belgium)
VIEW ePOSTER

18.40

APAC, a dual AntiPlatelet and AntiCoagulant, towards a local vascular targeting antithrombotic
R. Lassila (Russia)
VIEW ePOSTER

18.50

Investigation of the ADAMTS13 c.3178C>T mutation in hereditary and acquired thrombotic thrombocytopenic purpura
G. Sinkovits (Hungary)
VIEW ePOSTER

19.00

Rare bleeding disorders in the pediatric population of Northern Greece: a 10-year single center experience
A. Adramerina (Greece)
VIEW ePOSTER

19.10

Successful treatment and durable remission of refractory thrombotic thrombocytopenic purpura (TTP) with belimumab
Ryan R. Woods (USA)
VIEW ePOSTER